Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

Strangfeld A.; Richter A.; Siegmund B.; Herzer P.; Rockwitz K.; Demary W.; Aringer M.; Meissner Y.; Zink A.; Listing J.

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

【24h】

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

机译：用ToColizumab处理的类风湿性关节炎患者患者患者的风险与其他生物或常规合成DMARD治疗

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective To investigate the risk of developing lower intestinal perforations (LIPs) in patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ).

机译：目的探讨用Tocolizumab（TCZ）处理的类风湿性关节炎（RA）患者中肠穿孔（嘴唇）的风险。

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2017年第3期|共7页
作者
Strangfeld A.; Richter A.; Siegmund B.; Herzer P.; Rockwitz K.; Demary W.; Aringer M.; Meissner Y.; Zink A.; Listing J.;
展开▼
作者单位

German Rheumatism Res Ctr Dept Epidemiol Berlin Germany;

German Rheumatism Res Ctr Dept Epidemiol Berlin Germany;

Charite Univ Med Berlin Ctr Innere Med Gastroenterol &

Nephrol CC 13 Berlin Germany;

Sci Advisory Board Munich Germany;

Univ Med Dresden Div Rheumatol Dept Internal Med 3 Dresden Germany;

German Rheumatism Res Ctr Dept Epidemiol Berlin Germany;

German Rheumatism Res Ctr Dept Epidemiol Berlin Germany;

German Rheumatism Res Ctr Dept Epidemiol Berlin Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs [J] . Strangfeld A., Richter A., Siegmund B., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第3期

机译：用ToColizumab处理的类风湿性关节炎患者患者患者的风险与其他生物或常规合成DMARD治疗
2. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review [J] . Taras Gout, Andrew J. K. Östör, Muhammad K. Nisar Clinical Rheumatology . 2011,第11期

机译：常规DMARD或tocilizumab治疗的类风湿关节炎患者的下消化道穿孔：系统文献综述
3. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments [J] . Xie Fenglong, Yun Huifeng, Bernatsky Sasha, Arthritis & rheumatology. . 2016,第11期

机译：简要报告：类风湿关节炎患者接受Tofacitinib，Tocilizumab或其他生物疗法引起胃肠道穿孔的风险
4. Hyaluronic Acid-Gold Nanoparticle-Tocilizumab Complex for the Treatment of Rheumatoid Arthritis [C] . Hwiwon Lee, Min-Young Lee, Ki Su Kim, Society for biomaterials annual meeting and exposition . 2013

机译：透明质酸-金纳米颗粒-托珠单抗复合物治疗类风湿关节炎
5. Effects of resistance training on insulin sensitivity and markers of inflammation in rheumatoid arthritis patients treated with remicade. [D] . Gates, Donald L. 2009

机译：抵抗训练对接受线虫治疗的类风湿关节炎患者胰岛素敏感性和炎症标志物的影响。
6. Extended report: Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs [O] . A Strangfeld, A Richter, B Siegmund, -1

机译：扩展报告：与其他生物或常规合成DMARDs治疗相比使用tocilizumab治疗的类风湿关节炎患者肠穿孔降低的风险
7. SAT0244 Impact of 12 weeks of upadacitinib treatment on individual and composite disease measures in patients with rheumatoid arthritis and inadequate response to conventional synthetic or biologic dmards [O] . R. van Vollenhoven, R. Dore, K. Chen, 2018

机译：SAT0244 SAT0244 upadacitinib对类风湿性关节炎患者的个体和复合疾病措施的影响，对常规合成或生物DMARDs的反应不足

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

摘要

著录项

相似文献

相关主题

期刊订阅